Compugen to Participate in H.C. Wainwright Global Investment Conference Fireside Chat.
ByAinvest
Thursday, Aug 28, 2025 7:06 am ET1min read
CGEN--
The fireside chat will provide investors and financial professionals with an opportunity to gain insights into Compugen's pipeline and strategic direction. The company is developing two proprietary product candidates, COM701 and COM902, which are in Phase 1 development for cancer immunotherapies. COM701 is a potential first-in-class anti-PVRIG antibody, while COM902 is a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors [2].
In addition to these product candidates, Compugen's therapeutic pipeline includes early-stage immuno-oncology programs aimed at addressing new mechanisms to activate the immune system against cancer. The company is also involved in the development of bispecific and multispecific antibodies, with Rilvegostomig, a PD-1/TIGIT bispecific antibody derived from COM902, currently in Phase 3 development by AstraZeneca [2].
Compugen's shares are listed on the Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For further information, interested parties can contact Yvonne Naughton, Ph.D., Vice President, Head of Investor Relations and Corporate Communications, at ir@cgen.com or +1 (628) 241-0071.
References:
[1] https://www.marketscreener.com/news/compugen-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference-ce7c50dfde8af126
[2] https://finance.yahoo.com/news/compugen-present-h-c-wainwright-110000478.html
Compugen Ltd., a clinical-stage cancer immunotherapy company, announced that management will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference. The chat will be available on-demand on the company's website from September 5, 2025, for 90 days. Compugen is developing two proprietary product candidates, COM701 and COM902, for cancer immunotherapies.
Compugen Ltd., a clinical-stage cancer immunotherapy company, has announced that management will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference. The event, scheduled to take place on September 5, 2025, will be available on-demand on the company's website from the same date for 90 days [1].The fireside chat will provide investors and financial professionals with an opportunity to gain insights into Compugen's pipeline and strategic direction. The company is developing two proprietary product candidates, COM701 and COM902, which are in Phase 1 development for cancer immunotherapies. COM701 is a potential first-in-class anti-PVRIG antibody, while COM902 is a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors [2].
In addition to these product candidates, Compugen's therapeutic pipeline includes early-stage immuno-oncology programs aimed at addressing new mechanisms to activate the immune system against cancer. The company is also involved in the development of bispecific and multispecific antibodies, with Rilvegostomig, a PD-1/TIGIT bispecific antibody derived from COM902, currently in Phase 3 development by AstraZeneca [2].
Compugen's shares are listed on the Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For further information, interested parties can contact Yvonne Naughton, Ph.D., Vice President, Head of Investor Relations and Corporate Communications, at ir@cgen.com or +1 (628) 241-0071.
References:
[1] https://www.marketscreener.com/news/compugen-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference-ce7c50dfde8af126
[2] https://finance.yahoo.com/news/compugen-present-h-c-wainwright-110000478.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet